Compare Natera Inc. Common Stock (NTRA) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Sezzle Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Sezzle Inc trades at $122.66 (market cap $4.39B). The key difference: Natera Inc. Common Stock is far larger — about 13× Sezzle Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Sezzle Inc for 15 Days on average.
| NTRA | SEZL | |
|---|---|---|
Market Cap | $57.03B | $4.39B |
Volume | 1,131,157 | 424,843 |
Sector | Health | Financials |
52-Week High | $425.64 | $188.55 |
52-Week Low | $179.42 | $50.97 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $56.18B | $4.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Sezzle (SEZL) trades at $130.05, down 0.33% today, with a bullish technical signal and strong support near $127. The company demonstrates robust fundamentals, with Q2 2026 revenue growth of 51.7% year-over-year and a net income margin of 30.35%. Recent product launches like Sezzle Send and SezzleCash are driving user growth, while analyst consensus remains positive with a $168 price target.
Outlook is favorable given sustained earnings beats and raised guidance, but risks include competitive pressures in the BNPL sector and elevated valuation multiples. The stock offers growth potential if execution continues, though overbought technical indicators suggest near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
